Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
Search
Donate
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.
Conferences

HIV Glasgow 2014

The HIV Glasgow congress, the 12th International Congress on Drug Therapy in HIV infection, took place in Glasgow, UK, 2nd-6th November 2014.
Generic medicines

Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds

4 November 2014
Drug-resistant TB

One third of TB cases in Eastern European HIV clinic survey multi-drug resistant

5 November 2014
Treatment outcomes & life expectancy

Restoring and maintaining a high CD4 count possible for vast majority of people living with HIV in France

12 November 2014
New & experimental HIV treatments

Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

10 November 2014
New & experimental HIV treatments

Doravirine works as well as efavirenz with fewer CNS side-effects

10 November 2014
Changing treatment

Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

7 November 2014
PrEP programmes & uptake

Truvada PrEP use rising in United States, especially among men

7 November 2014
Retention & linkage to care

Australia performs best in HIV treatment cascade – 62% with undetectable viral load

4 November 2014
Contraception

Efavirenz compromises hormonal contraceptive implant

3 November 2014
Treatment guidelines

Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

3 November 2014
Sign up for our email bulletins.
Sign up

Editors’ picks from other sources

Starting treatment

Early Initiation of Combo Antiretrovirals Gaining Support

Evidence continues to support the initiation of combined antiretroviral therapy soon after HIV infection, researchers report. In fact, the likelihood of the CD4/CD8 ratio normalizing was almost three times greater if antiretroviral therapy was initiated within 6 months of HIV infection than if it was delayed for more than 6 months, according to John Thornhill, MD, from Imperial College London in the United Kingdom, and his team.
Medscape (requires registration)
7 Nov 14
More editors' picks

About us

NAM is a charity based in the United Kingdom. We work to change lives by sharing information about HIV & AIDS. We believe independent, clear and accurate information is vital in the fight against HIV & AIDS.

Our information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Read more about us

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram
Subscribe to emails & newsfeeds

Login to our clinic portal
Donate

Visit NAM’s other websites: clinic.nam.org.uk | infohep.org | prepineurope.org | about-hiv.info | pro-vich.info | hiv-lens.org

© NAM Publications 2022, all rights reserved. NAM is not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Footer menu

Show — Footer menu Hide — Footer menu
  • Contact
  • Jobs
  • Terms of Use
  • Accessibility
  • Privacy Policy
  • Cookies
  • Manage cookies